Burney Co. Has $988,000 Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Burney Co. lowered its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 52.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 34,476 shares of the specialty pharmaceutical company’s stock after selling 38,157 shares during the period. Burney Co.’s holdings in Collegium Pharmaceutical were worth $988,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Pacer Advisors Inc. lifted its position in Collegium Pharmaceutical by 31.8% during the 2nd quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after buying an additional 821,541 shares in the last quarter. Rubric Capital Management LP raised its stake in shares of Collegium Pharmaceutical by 27.2% in the second quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock worth $75,139,000 after acquiring an additional 499,473 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of Collegium Pharmaceutical by 43.6% during the third quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock worth $27,461,000 after purchasing an additional 215,874 shares in the last quarter. Emerald Advisers LLC grew its stake in shares of Collegium Pharmaceutical by 27.2% during the third quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock valued at $31,967,000 after purchasing an additional 177,129 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after purchasing an additional 175,892 shares in the last quarter.

Analyst Ratings Changes

Several research analysts have issued reports on COLL shares. Piper Sandler reaffirmed a “neutral” rating and set a $37.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 11th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a report on Friday, January 10th. Finally, StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $43.80.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the company’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the completion of the sale, the executive vice president now owns 119,184 shares of the company’s stock, valued at approximately $3,937,839.36. This represents a 18.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Stock Up 1.5 %

NASDAQ:COLL opened at $33.46 on Friday. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a 12-month low of $28.39 and a 12-month high of $42.29. The stock’s fifty day simple moving average is $30.52 and its 200-day simple moving average is $34.09. The firm has a market capitalization of $1.08 billion, a P/E ratio of 14.42 and a beta of 0.82.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.